Phase 3 CUPID-C trial (151 anti-IgE-naive patients with chronic spontaneous urticaria uncontrolled by antihistamines): dupilumab vs placebo improved itch (ISS7 difference -2.54) and urticaria activity (UAS7 -4.65) at week 24; adverse events were similar.
RCTn = 151
Casale et al. Dupilumab in Patients With Chronic Spontaneous Urticaria: Phase 3 LIBERTY-CSU CUPID Randomized Clinical Trials